# A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects

> **NCT01793649** · PHASE1 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 7 (actual)

## Conditions studied

- Cystic Fibrosis
- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** GS-5737

## Key facts

- **NCT ID:** NCT01793649
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2014-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01793649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01793649, "A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01793649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*